Spastic Paraplegia Type 4 Latest Advances

Expanding the clinical and mutational spectrum of hereditary spastic paraplegia type 4 in a cohort of patients from central China.

Journal: Frontiers in genetics

Published: January 31, 2026

Fampridine in Hereditary Spastic Paraplegia Type 4 With SPAST Variant c.683-2A>C: A Case Report.

Journal: The American journal of case reports

Published: January 07, 2026

A GJA1 Variant Triggers Earlier SPG4 Onset by Destabilizing Deubiquitinase VCPIP1 to Lower SPASTIN Levels.

Journal: Movement disorders : official journal of the Movement Disorder Society

Published: November 20, 2025

SPG4 and Dementia: Expanding the Clinical Spectrum.

Journal: Annals of clinical and translational neurology

Published: November 14, 2025

Serum NfL, but not GFAP, differentiates primary lateral sclerosis from adrenomyeloneuropathy and hereditary spastic paraplegia type 4.

Journal: Amyotrophic lateral sclerosis & frontotemporal degeneration

Published: September 17, 2025

Genotype-Phenotype Distinctions in Spastic Paraplegia 4 Reveal HDAC6 as a Therapeutic Target.

Journal: bioRxiv : the preprint server for biology

Published: August 12, 2025

Modeling spastic paraplegia 4 with corticospinal motor neuron-enriched cortical organoids reveals genotype-phenotype and HDAC6-targetable pathology.

Journal: Cell reports

Published: July 31, 2025

Expanding the Phenotypic Spectrum of SPG4: Autism Spectrum Disorder in Early-Onset and Complex SPAST-HSP and Case Study.

Journal: Genes

Published: July 17, 2025

Spinal cord structural changes in SPG4: insights from a large cohort using advanced neuroimaging.

Journal: Journal of neurology

Published: June 18, 2025

Intracerebroventricular SPAST-AAV9 gene therapy prevents manifestation of symptoms in a mouse model of SPG4 hereditary spastic paraplegia.

Journal: Molecular therapy : the journal of the American Society of Gene Therapy

Published: April 14, 2025

Structural brain changes contributing to motor signs in pure hereditary spastic paraplegia type 4.

Journal: Journal of neurology

Published: February 19, 2025

Subclinical involvement of central nervous system structures other than motor or sensory tracts in SPG3A and SPG4 patients.

Journal: BMC neurology

Published: January 10, 2025

Spastic Paraplegia Type 4 Latest Advances

Find the Latest Research About Spastic Paraplegia Type 4

Expanding the clinical and mutational spectrum of hereditary spastic paraplegia type 4 in a cohort of patients from central China.

Expanding the clinical and mutational spectrum of hereditary spastic paraplegia type 4 in a cohort of patients from central China.

Fampridine in Hereditary Spastic Paraplegia Type 4 With SPAST Variant c.683-2A>C: A Case Report.

Fampridine in Hereditary Spastic Paraplegia Type 4 With SPAST Variant c.683-2A>C: A Case Report.

A GJA1 Variant Triggers Earlier SPG4 Onset by Destabilizing Deubiquitinase VCPIP1 to Lower SPASTIN Levels.

A GJA1 Variant Triggers Earlier SPG4 Onset by Destabilizing Deubiquitinase VCPIP1 to Lower SPASTIN Levels.

SPG4 and Dementia: Expanding the Clinical Spectrum.

SPG4 and Dementia: Expanding the Clinical Spectrum.

Serum NfL, but not GFAP, differentiates primary lateral sclerosis from adrenomyeloneuropathy and hereditary spastic paraplegia type 4.

Serum NfL, but not GFAP, differentiates primary lateral sclerosis from adrenomyeloneuropathy and hereditary spastic paraplegia type 4.

Genotype-Phenotype Distinctions in Spastic Paraplegia 4 Reveal HDAC6 as a Therapeutic Target.

Genotype-Phenotype Distinctions in Spastic Paraplegia 4 Reveal HDAC6 as a Therapeutic Target.

Modeling spastic paraplegia 4 with corticospinal motor neuron-enriched cortical organoids reveals genotype-phenotype and HDAC6-targetable pathology.

Modeling spastic paraplegia 4 with corticospinal motor neuron-enriched cortical organoids reveals genotype-phenotype and HDAC6-targetable pathology.

Expanding the Phenotypic Spectrum of SPG4: Autism Spectrum Disorder in Early-Onset and Complex SPAST-HSP and Case Study.

Expanding the Phenotypic Spectrum of SPG4: Autism Spectrum Disorder in Early-Onset and Complex SPAST-HSP and Case Study.

Spinal cord structural changes in SPG4: insights from a large cohort using advanced neuroimaging.

Spinal cord structural changes in SPG4: insights from a large cohort using advanced neuroimaging.

Intracerebroventricular SPAST-AAV9 gene therapy prevents manifestation of symptoms in a mouse model of SPG4 hereditary spastic paraplegia.

Intracerebroventricular SPAST-AAV9 gene therapy prevents manifestation of symptoms in a mouse model of SPG4 hereditary spastic paraplegia.

Structural brain changes contributing to motor signs in pure hereditary spastic paraplegia type 4.

Structural brain changes contributing to motor signs in pure hereditary spastic paraplegia type 4.

Subclinical involvement of central nervous system structures other than motor or sensory tracts in SPG3A and SPG4 patients.

Subclinical involvement of central nervous system structures other than motor or sensory tracts in SPG3A and SPG4 patients.